BioSpace News Archive

Henry Schein, Inc. announced plans to enter the upper- and lower-extremities specialty segment of the orthopedic market in line with our long-standing strategy.

Scribe Therapeutics Inc. today announced the appointments of Aarif Khakoo, M.D., M.B.A., as Chief Scientific Officer and Head of Research and Development (R&D), and Maria Mirotsou, M.Sc., Ph.D., as Vice President of Discovery Biology.

ImmunoScape and MiNK Therapeutics, Inc today announced a collaboration agreement to discover and develop next-generation TCR therapies against novel targets in solid tumors.

Daré Bioscience, Inc., a leader in women’s health innovation, announced positive topline results from the Phase 1 study evaluating the pharmacokinetics, safety, and exploratory efficacy of DARE-PDM1.

SciTech Development (“SciTech” or the “Company”), a clinical-stage pharmaceutical company with a novel and patented drug delivery platform, today announced that the company has dosed the first patient in its Phase 1 clinical trial with lead cancer drug candidate, ST-001 nanoFenretinide.

W. L. Gore & Associates (Gore) announced the first patient implantation of the GORE® Ascending Stent Graft in the ARISE II Trial, an exciting step in the development of treatments for pathologies involving the ascending aorta using endovascular repair rather than traditional open surgery.

Akebia Therapeutics today announced that John Butler , Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th , 2024.

Enveric Biosciences announced the company will participate in Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco.

Pulse Biosciences, Inc. today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

Evolus, Inc. announced it has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in second half of 2024 and commercialization under the brand name Estyme® fillers in 2025.